Revolade 25 mg (Eltrombopag (Eltrombopag Olamine) TABLET) 25 MG

REVOLADE 25 MG tablets contain eltrombopag olamine, a medication used to support platelet production. This oral treatment is commonly prescribed for conditions affecting blood cell counts.

Strength

25 MG

Pack Size

14/28

Manufacturer / TM Owner

NOVARTIS PHARMACEUTICALS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

REVOLADE 25 MG tablets are primarily used to increase platelet levels in individuals with certain blood disorders. Eltrombopag olamine works by stimulating the bone marrow to produce more platelets, which are essential for blood clotting. This medication is often considered when other treatments for low platelet counts have not been effective.

Side Effects

Common effects of REVOLADE 25 MG tablets may include nausea, dizziness, and fatigue. Some users might experience changes in liver function, so regular monitoring is advised. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

REVOLADE 25 MG tablets should be handled with care, especially by individuals with liver conditions. It is important to follow the prescribed dosage and avoid self-adjustment. Pregnant or breastfeeding women should discuss potential risks with their healthcare provider.

Avoid Interactions

REVOLADE 25 MG tablets may interact with certain medications, including those metabolized by the liver. Alcohol consumption should be limited, as it can affect liver function. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

REVOLADE 25 MG tablets are used to increase platelet levels in individuals with certain blood disorders.

REVOLADE 25 MG tablets are taken orally, typically once daily. Follow your healthcare provider's instructions for the best results.

Common side effects may include nausea, dizziness, and fatigue. Regular monitoring is advised to check for changes in liver function.

REVOLADE 25 MG may interact with certain medications, especially those metabolized by the liver. Always consult your healthcare provider before combining medications.

Pregnant or breastfeeding women should discuss the potential risks and benefits with their healthcare provider before taking REVOLADE 25 MG.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.